Pfizer to Offer Free Public Access to Mental Health Assessment Tools
- Details
- Category: Pfizer
As part of its commitment to improving the quality of patient care, Pfizer (NYSE: PFE) will make available assessment scales used by physicians and others in the healthcare community to support the evaluation and diagnosis of patients suffering from certain mental disorders.
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) reported results for the second quarter of 2010 which featured data on key marketed and investigational compounds in its oncology, diabetes and cardiovascular franchises, and growth in sales and EPS.
GlaxoSmithKline statement in response to FDA announcement on TIDE trial
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline [NYSE: GSK] confirmed that it will suspend enrollment of new patients in the Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) clinical trial at the request of the U.S. Food and Drug Administration (FDA) pending FDA review of recommendations from its Advisory Committee meeting July 13-14.
Abbott Reports Strong Second Quarter Results
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2010.
Novartis delivers strong financial performance in second quarter
- Details
- Category: Novartis
Novartis delivered a strong performance in the second quarter of 2010 - with the rapid expansion of recently launched products and important regulatory approvals achieved for new medicines - as the Group made progress on its agenda on innovation, growth and productivity.
Bayer Schering Pharma enters strategic partnership with Hospital in China
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, has entered into a research collaboration agreement with The People's Liberation Army General Hospital (301 Hospital) in Beijing, China.
FDA Grants Priority Review Designation to Denosumab
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer.
More Pharma News ...
- Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
- Amgen Foundation and Changemakers Launch Global Online Competition to Empower Patients
- GlaxoSmithKline (GSK) responds to Senate Finance Committee letter
- Pfizer Strengthens Manufacturing Capabilities in Asia
- Data support Avandia (rosiglitazone maleate) cardiovascular safety profile
- Testing for Human Papillomavirus Genotypes 16 and 18 Detects Cervical Pre-Cancer Missed by Pap Test
- Lilly to Acquire Alnara Pharmaceuticals